Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study by Benson, Eric A. et al.
RESEARCH ARTICLE
Carboplatin with Decitabine Therapy, in
Recurrent Platinum Resistant Ovarian Cancer,
Alters Circulating miRNAs Concentrations: A
Pilot Study
Eric A. Benson1,2,3*, Todd C. Skaar1,2,8, Yunlong Liu4,5, Kenneth P. Nephew6,7,8,
Daniela Matei1,3,7,8,9
1 Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of
America, 2 Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana,
United States of America, 3 VARoudebush Hospital, Indiana University School of Medicine, Indianapolis,
Indiana, United States of America, 4 Department of Medical and Molecular Genetics, Indiana University School
of Medicine, Indianapolis, IN, United States of America, 5 Center for Computational Biology and Bioinformatics,
Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 6 Departments of
Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana, United States of
America, 7 Department of Obstetrics andGynecologyMedical Sciences Program IndianaUniversity School of
Medicine, Indianapolis, Indiana, United States of America, 8 Indiana University Melvin and Bren Simon Cancer
Center, Indianapolis, Indiana, United States of America, 9 Department of Biochemistry andMolecular Biology,




Plasma miRNAs represent potential minimally invasive biomarkers to monitor and predict
outcomes from chemotherapy. The primary goal of the current study—consisting of patients
with recurrent, platinum-resistant ovarian cancer—was to identify the changes in circulating
miRNA concentrations associated with decitabine followed by carboplatin chemotherapy
treatment. A secondary goal was to associate clinical response with changes in circulating
miRNA concentration.
Methods
Wemeasured miRNA concentrations in plasma samples from 14 patients with platinum-
resistant, recurrent ovarian cancer enrolled in a phase II clinical trial that were treated with a
low dose of the hypomethylating agent (HMA) decitabine for 5 days followed by carboplatin
on day 8. The primary endpoint was to determine chemotherapy-associated changes in
plasma miRNA concentrations. The secondary endpoint was to correlate miRNA changes
with clinical response as measured by progression free survival (PFS).
Results
Seventy-eight miRNA plasma concentrations were measured at baseline (before treatment)
and at the end of the first cycle of treatment (day 29). Of these, 10 miRNAs (miR-193a-5p,
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miR-375, miR-339-3p, miR-340-5p, miR-532-3p, miR-133a-3p, miR-25-3p, miR-10a-5p,
miR-616-5p, and miR-148b-5p) displayed fold changes in concentration ranging from -2.9
to 4 (p<0.05), in recurrent platinum resistant ovarian cancer patients, that were associated
with response to decitabine followed by carboplatin chemotherapy. Furthermore, lower con-
centrations of miR-148b-5p after this chemotherapy regimen were associated (P<0.05) with
the PFS.
Conclusions
This is the first report demonstrating altered circulating miRNA concentrations following a
combination platinum plus HMA chemotherapy regiment. In addition, circulating miR-148b-
5p concentrations were associated with PFS and may represent a novel biomarker of thera-
peutic response, with this chemotherapy regimen, in women with recurrent, drug-resistant
ovarian cancer.
Introduction
Each year, over 200,000 women are diagnosed with ovarian cancer worldwide; more than
21,000 of those are American. Approximately 15,000 American women die from epithelial
ovarian cancer (EOC) every year; of the various types of ovarian cancer, high grade serous
ovarian cancer is the most common (HGSOC) [1, 2]. For HGSOC identification, a well-
established serum biomarker is the cancer antigen 125 (CA-125). Although CA-125 identifies
most late stage primary and relapsed disease and largely correlates with disease burden, CA-
125, in terms of sensitivity and specificity, is not predictive of the risk of relapse or chemothera-
peutic response [2, 3]. In general, EOC biomarkers are needed, and circulating miRNAs, which
have associated with disease outcome [4], may represent a novel source of clinically informa-
tive ovarian cancer biomarkers.
MicroRNAs (miRNAs) are short RNAs differentially expressed in many disease states,
including cancer. They alter the target protein synthesis by regulating post-transcriptional gene
expression [5–7]. miRNAs are released into the plasma by tissues and tumors [6, 8]. miRNAs
are relatively heat stable in both whole blood and plasma [9, 10]. Circulating miRNAs have
been associated with early detection and prognosis of EOC [11, 12] and may predict therapeu-
tic response.
First-line EOC treatments utilize platinum based chemotherapies. These chemotherapies
have been shown to change, within tissues, miRNA expression [13–16]. In this study, plasma
miRNA concentrations were measured from a previously completed phase II clinical trial [17].
In this trial, 17 subjects with platinum resistant recurrent ovarian cancer were tested for effi-
cacy and tolerability of a combination regimen of low dose decitabine (5-aza-2’-deoxycytidine;
a DNAmethyltransferase inhibitor) and carboplatin. The main objective of the clinical trial
was to test the hypothesis that treatment with decitabine would resensitize ovarian tumors to
carboplatin. The trial was based on previous preclinical studies indicating that reversal of DNA
hypermethylation induces re-expression of tumor suppressor and differentiation associated
genes that would restore sensitivity to platinum [18]. The results of the trial demonstrated pro-
longed progression free survival (PFS of ~10 months) and a promising rate of objective
response rates of 35% [17]. Taking advantage of the clinically annotated plasma samples col-
lected for this trial, we determined in response to decitabine followed by carboplatin
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chemotherapy the changes in circulating miRNAs concentrations. Secondarily, miRNA
changes were associated with clinical response.
Methods
Patient population
The open label phase II clinical trial and response rates were previously described by Matei
et al [17]. Briefly, all patients had platinum resistant EOC and all but one patient had measur-
able disease as defined by Response Evaluation Criteria in Solid Tumor (RECIST). The patient
with non-measureable disease had a CA-125 greater than twice the upper limit of normal and
ascites. All patients in this study were older than 18 years, had greater than 3 months life expec-
tancy, and had an Eastern Cooperative Group performance status of 0 or 1. Patients could have
received unlimited number of prior cytotoxic therapies; however, they were excluded if they
had a prior history of brain metastases, an allergy to carboplatin, uncontrolled medical issues,
or grade 2 or higher neuropathy. All patients signed informed consent, and the protocol was
approved by the Indiana University Institutional Review Board.
Treatment plan
Each chemotherapy cycle lasted 4 weeks and consisted of decitabine (Eisai, Tokyo, Japan)
given intravenously at 10 mg/m2 daily for 5 days; followed by, carboplatin (Bristol Meyers
Squibb, New York, New York) given intravenously at an AUC5 on day 8 [17]. Additionally,
peg-filgastrim (Amgen, Thousand Oaks, CA) was given on day 9 to prevent prolonged myelo-
suppression. Treatment was continued until disease progression or intolerable toxicity.
RNA extraction from plasma
miRNAs were extracted from the plasma following a previously published protocol [9]. Briefly,
plasma samples were thawed on ice to ~4°C, and centrifuged at 1500 RCF, 4°C for 10 minutes.
Fifty μL of plasma was extracted following the Qiagen miRNeasy plasma protocol (Qiagen,
Valencia, CA). Following the Qiazol lysis step, C. elegans miR-39 miRNA (cel-miR-39) was
added (5 μL of 5 nM stock) as an internal control for extraction efficiency and normalization.
Additionally, 0.3 μL of a stock (0.8 μg/μL) Bacteriophage M2 RNA was added per 200 μL Qia-
zol buffer to increase miRNA yield. miRNAs were eluted from the purification column twice in
30 μL RNase/DNase free water (total 60 μL) and stored at -80°C.
Statistical analysis
In this pilot study, the primary outcome was the analysis of the difference in plasma miRNA
concentrations between the before and after chemotherapy treatment. All values were normal-
ized to the cel-miR-39 spiked in control. Statistical significance (p-value) in the comparisons of
groups was determined by paired T-test. In Table 1, the baseline comparison was two tailed T-
test. The heatmaps were completed in Partek software using the delta delta CT (ddCT) values.
The following parameters were used for the heatmap: no scale; the distance vector = Spearman
rank correlation; and the clustering = average. Of note, 1 is no fold-change, while 2 is a dou-
bling of fold change.
Kaplan Meier curve
Progression free survival (PFS) analysis was conducted with “survival” package in R. Samples
were divided into 2 groups by the median value of the “–delta delta CT” values. The log-rank
test was performed in R to assess the association between miRNA concentration (high vs. low)
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with the time to progression, and p-value less than 0.05 was considered significant. Kaplan-
Meier curves were used to visually examine the cumulative probability of remaining progres-
sion free over time for miRNA sub-groups.
Results
Plasma sample selection
Briefly, whole blood was collected in EDTA containing tubes, and then centrifuged to plasma.
Samples used for microRNA analysis were collected at two time points: at baseline (prior to the
start of the first cycle of treatment); and on day 29 after treatment initiation (post the first cycle
of chemotherapy; Fig 1). Samples from 14 of the 17 patients were available for this miRNA
analysis. The remaining 3 samples were not analyzed because of insufficient plasma. Samples
were analyzed after the first cycle to allow for early miRNA analysis, which may provide evi-
dence toward their future use in early clinical decision-making.
miRNA selection and concentration
Ninety-three miRNAs were selected for measurement in the 28 samples (14 baseline and 14 after
treatment). To select the miRNAs, real-time qPCRmiRNAOpenArrays (Life Technologies,
Carlsbad, CA), which measure 756 miRNAs, were used to analyze a pooled baseline sample (14
samples) versus a pooled day 29 sample (14 after treatment samples). RNA was extracted from
each individual sample and pooled. The miRNAs that were easily quantifiable and with the largest
difference between the baseline and day 29 were selected for further analysis of individual samples.
The 93 miRNAs selected were analyzed by a custom real-time PCR Taqman miRNA low density









miRNA Fold change p valuea Fold change p valuea Fold change p valuea Fold difference p valueb
hsa-miR-193a-5p -1.70* 0.033 -1.97 0.058 -1.40 0.37 1.36 0.58
hsa-miR-375 -1.97* 0.039 -2.14* 0.043 -1.76 0.38 1.03 0.97
hsa-miR-339-3p 1.92* 0.049 1.09 0.80 4.05* 0.012 2.05 0.22
hsa-miR-340-5p 1.97 0.079 1.52 0.47 2.79* 0.048 1.35 0.69
hsa-miR-148b-5p -1.62 0.15 -2.86* 0.0495 1.33 0.16 3.23* 0.046
hsa-miR-133a-3p 1.49 0.19 1.25 0.66 1.88* 0.015 -1.13 0.89
hsa-miR-25-3p -1.22 0.40 -1.82* 0.042 1.40 0.339 1.01 0.99
hsa-miR-10a-5p 1.25 0.47 -1.14 0.79 2.00* 0.024 1.40 0.47
hsa-miR-616-5p -1.07 0.67 -1.43 0.094 1.38 0.116 1.97* 0.049
hsa-miR-532-3p -1.11 0.70 -1.72 0.11 1.62 0.252 2.84* 0.044
1The change plasma miRNA concentrations from baseline to after treatment with decitabine and carboplatin.
2,3Subgroup analysis of non-responsive subjects (progressed before 7 cycles of therapy) and responsive subjects (did not progress before 7 cycles of
therapy), respectively.
4Plasma miRNA concentrations are fold differences between responders and non-responders using the after chemotherapy treatment miRNA
concentrations. Non-responsive subjects are those that had < 6 months of treatment prior to progression of ovarian cancer; Responsive subjects are
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array (TLDA) (Life Technologies). For final analysis, of the original 93 miRNAs, 78 had accept-
able qPCR curves. Plasma samples were analyzed at each of the two time points (baseline and day
29; 14 patients each), and the same TLDA card was used for both samples. Data are expressed as
relative concentrations based on the CT values that have been normalized to the C. elegans
miRNA (5 μL of 5 nM) spiked into the plasma as an internal control.
Patient characteristics
Fourteen of the original 17 patients in the parent trial had plasma samples available for miRNA
analysis. Disease status was assessed using RECIST and CA-125 criteria every 2 cycles of che-
motherapy. Chemotherapy was discontinued with recording of an intolerable toxicity or dis-
ease progression. Disease progression in patients prior to 6 cycles (n = 8) of chemotherapy
were considered non-responders; and disease progression after 6 cycles (n = 6) of chemother-
apy were considered responders. Of the responders, one patient remained without progressive
disease for ~17 months. Each patient completed the number of cycles of chemotherapy shown
in Fig 2. The responders and non-responders are separated by the red line.
Circulating miRNAs change in response to chemotherapy
The primary endpoint of our study was to determine changes in circulating miRNAs follow-
ing decitabine/carboplatin chemotherapy. Prior to chemotherapy (baseline) and prior to the
start of cycle 2 (day 29), plasma concentration were compared for 78 miRNAs. All 78
miRNA were visualized using a Spearman ranked heatmap (Fig 3; same patient identifica-
tion numbers as in Fig 2). In the heatmap, patients tended to discriminate, after
Fig 1. Study Design: Platinum resistant ovarian cancer subjects treated with decitabine and carboplatin. Fourteen platinum resistant ovarian cancer
patients were treated with decitabine/carboplatin in a phase II clinical trial. For the first chemotherapy cycle, decitabine was given daily for 5 days; followed by
carboplatin given on day 8. miRNA analysis used plasma samples collected at baseline (prior to start of cycle one treatment) and at day 29 (prior to start of
second cycle).
doi:10.1371/journal.pone.0141279.g001
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chemotherapy, into groups. Three distinct patient groups were visualized: group1 (patients
#1, #3, #4, #7, #10, and #11); group 2 (patients #8, #13, and #14); and group 3 (patients #2,
#5, #6, and #12). Groupings were based on the comparison of within patient similarities of
the relative changes in miRNA concentrations. For instance, group 3, patient #12 had
increased, with treatment, total miRNA concentrations compared to other patients within
the group. Patient #12’s miRNAs concentrations changed in the same relative proportions
as those recorded for patient #6. Thus, patient #12 and #6 were similarly grouped. As these
visualized groupings suggest, this chemotherapy regimen may induce distinct changes in
circulating miRNA concentrations in subpopulations.
Next, the changes in the concentrations of individual circulating miRNAs were evaluated
after chemotherapy treatment. Following decitabine/carboplatin therapy as shown in Table 1
(individual patient’s miRNA changes shown in S1 Fig), two microRNAs decreased in concen-
tration. miR-193a-5p and miR-375 had respective fold-changes of -1.7 and -2.0 (p<0.05).
Additionally, the fold change increased 1.9 (P<0.05) for miR-339-3p.
When the responder subgroup was analyzed, 4 miRNAs, miR-339-3p, miR-340-5p, miR-
133a, and miR-10a, increased with a fold range 1.9 to 4.1 (Table 1; S2 Fig). The subgroup of
non-responders had three decreasing miRNAs, miR-375, and miR-25-3p, miR-148b-5p. miR-
148b-5p had largest decrease (p<0.05) in miRNA concentration (Table 1; S3 Fig).
To determine if individual miRNAs were associated with treatment response, we compared
in responders with non-responders the post-treatment concentrations of circulating miRNAs
(Fig 2). Three miRNAs, miR-616, and miR-532-3p, miR-148b-5p, were increased in respond-
ers (Table 1; S4 Fig). Of these miRNA, miR-148b-5p increase (3.2 fold) in responders was con-
sistent with the subgroup analysis, noted above, revealing its decrease in concentration (2.86)
in non-responders.
Lower miR-148b-5p concentrations predicted worse progression free
survival
Next, a Kaplan Meier PFS analysis was used to evaluate if any of the changes in miRNA con-
centrations predicted treatment response. To make more applicable to the clinical setting,
patients who progressed during the 1st cycle (4 patients) were removed from the analysis. For
those patients, progression would be observed using standard diagnostics, and a predictive
Fig 2. Number of cycles of chemotherapy completed by each subject. The patients’ are numbered and ordered based on the number of received cycles
of chemotherapy. Patients were separated by a red line to distinguish chemotherapy responders and non-responders. Responders remained free of disease
progression for at least 6 cycles (n = 6); and non-responders remained free of disease progression less than 6 cycles (n = 8). Each cycle was 28 days long.
doi:10.1371/journal.pone.0141279.g002
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biomarker would be unnecessary. As shown in Fig 4 of the Kaplan Meier analysis, lower
(p = 0.015) miR-148b-5p concentration on day 29 associated with disease progression. Baseline
miR-148b-5p concentration was low (Fig 4, inset); and in non-responders, miR-148-5p
decreased in concentration largely after 1 month of treatment.
Discussion
Our study has several important findings. First, decitabine/carboplatin chemotherapy induced
changes in circulating miRNA concentrations in patients with platinum-resistant recurrent
ovarian cancer. Second, subgroup analysis revealed miRNAs changed distinctly in nonre-
sponders vs. responders. Third, miR-148-5p predicts possible clinical outcome.
Fig 3. Circulating miRNAs visually differentiate patients into different groups. Patients are numbered (left side of Fig 3) according to convention
established, see Fig 2. Patients grouped visually based on clustering (red numbers = group 1, green numbers = group 2, and blue numbers = group 3). The
clustering was based on similarity between the changes in miRNA concentrations between baseline (dCT baseline) and after chemotherapy treatment (dCT
treatment). Blue = decreased concentrations after chemotherapy, Red = increased concentrations after treatment.
doi:10.1371/journal.pone.0141279.g003
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Fig 4. Lower concentrations of miR-148-5p after decitabine/carboplatin chemotherapy compared to baseline predicts worse progression free
survival. For the Kaplan Meier progression free survival curve, patient samples were divided into 2 groups by the median value of the “–delta delta CT”
values (post treatment value subtracted from baseline value). The log-rank test was between plasmamiRNA concentration (high [red line] vs. low [black line])
with the time to non-response, and p value less than 0.05 was considered significant. The inset plots the raw CT values of all patient samples for miR-148-5p,
dashed lines—non-responders, solid lines—responders.
doi:10.1371/journal.pone.0141279.g004
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Consistently in all patient samples, this chemotherapy regimen induced changes in three
circulating miRNAs miR-375, miR-339, and miR-193a. Of these miRNA, miR-193a has been
studied previously in human EOC. miR-193a is a tumor suppressor, and overexpression of
miR-193a in human EOC cells leads to increased apoptosis [19]. The circulating concentration
of miR-193a, in our study, decreased (-1.7-fold) after chemotherapy treatment. The relation-
ship between circulating and tumor miR-193a may warrant further study. Changes in circulat-
ing miRNAs common to all patients may be a marker of chemotherapy compliance and dose
response.
The observed changes in circulating miRNA concentrations in patients with recurrent ovar-
ian cancer enrolled in this study are similar to previously reported chemotherapy-induced
changes in circulating miRNA in patients with melanoma. In that setting, circulating miRNAs
predicted drug dose response to dacarbazine and interferon-alfa-2b [20]. miRNA fold changes
compared favorably to our study’s -2 to 4 fold changes. The fold changes observed in our study
appear reasonable and consistent with those recorded by others.
Subgroup analysis revealed distinctions in miRNA concentrations between non-responders
and responders. These distinctions in miRNAs may be a marker of specificity for a subgroup.
In the subgroup analysis of non-responders, chemotherapy decreased two additional miRNAs,
miR25-3p, and miR148b-5p. Suggesting that these may be specific for a non-responder.
miR-148b-5p predicts possible clinical outcomes. The circulating miR-148b-5p concentra-
tion was 3.2 fold higher in our study after decitabine/carboplatin chemotherapy in patients
with longer PFS: miR-148b-5p decreased in patients with shorter PFS. Circulating miR-148b-
5p has not been reported previously; though, intracellular miR-148-5p has been studied. miR-
148b-5p is overexpressed in ovarian cancer tissue; but its overexpression is not associated with
histological subtypes [21]. Other studies have shown that changes in intracellular miR-148
(also called miR-148a, and miR-148a-5p) expression, located on chromosome 7, are associated
with ovarian cancer outcomes [22–27]. To our knowledge, this is the first study to show that
miR-148b, which is located on chromosome 12, is associated with clinical outcomes after treat-
ment with any chemotherapy.
Our study has a couple of strengths. The first strength was a well-described group of
patients. This study focused on decitabine/carboplatin chemotherapy induced changes in cir-
culating miRNA focused in recurrent ovarian cancer. Many other studies have been con-
founded, for example, by either heterogeneous cancer patient population or additional
treatments in conjunction with the chemotherapy. For instance, measuring circulating miR-
NAs as biomarkers for neoadjuvant chemotherapy in breast cancer, one study included surgery
and a very heterogeneous population, and the other also included surgery [28, 29]. The results
of the studies were not consistent with each other. In the study with chemotherapy followed by
surgery, the fold changes in circulating miRNA ranged from 1.5 to 4. In the other study that
included patients with the many different stages of breast cancer, the subjects had miRNA fold
changes from 1 to 15,000 [28]. Additionally from these studies, circulating miRNA changes
induced by chemotherapy were difficult to differentiate from changes caused by surgery. A sec-
ond strength of our study was the timing of sample collection. Our study samples were col-
lected early in the treatment regimen compared to the studies listed. Our study evaluated
changes in circulating miRNA after 1 cycle of chemotherapy; these other studies analyzed
changes in circulating miRNAs after 4 cycles of treatment. We propose that evaluating circulat-
ing miRNAs after only 1 cycle allows for early clinical decision-making. An important early
decision is whether to continue the current chemotherapy regimen or change to another regi-
men. This decision is especially important for patients with recurrent ovarian cancer, as the
progression of disease may be rapid.
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A secondary issue is the appropriate utilization of the heatmap. Our heatmap visually iden-
tified groups of patients by differences in miRNA concentrations. Though descriptive, the heat-
map highlights circulating miRNAs are numerous and potentially altered by chemotherapy.
Circulating miRNAs in combination may be a biomarker of chemotherapy response worth
exploring in future studies.
We recognized the limitations of our study, including the small sample size. However,
despite the small number of patients analyzed, we were still able to detect differences in chemo-
therapy-induced changes in circulating miRNAs. We acknowledge that these specific miRNA
changes may be limited to this regimen, which is not a standard therapy for ovarian cancer
patients, and that the patients had previously received a variety of different treatment regimens
before starting this trial. Finally, this study included a single time point, a common limitation
of these types of studies, and the results suggests that a time course analysis may be warranted
in future studies of chemotherapy induced changes in circulating miRNAs.
In conclusion, our study indicates that a carboplatin and decitabine chemotherapy regimen
induces changes in circulating miRNAs concentrations that may be predictors of clinical
response to this regimen. Our results further indicate that circulating miRNAs may not directly
reflect the tumor miRNA expression. These studies indicate that future studies focused on
identifying circulating miRNAs predictive of chemotherapy response are warranted.
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S1 Fig. miR-148-5p and miR-25-3p ΔΔ CT changes in patients 1–14. The ΔΔ CT change for
the significantly changed miRNAs based on p< 0.05 from the “All subjects treatment/baseline-
” column in Table 1 are shown for individual patients (listed on x-axis). Red columns–nonre-
sponders (patients 1–8); blue columns–responders (patients 9–14).
(TIF)
S2 Fig. miR-340-5p, miR-133a-3p, and miR-10a-5p ΔΔ CT changes in patients 1–14. ΔΔ CT
change for the significantly changed from the “Treatment comparison in responsive subjects”
column in Table 1 are shown for individual patients (listed on x-axis). miR-339-3p, which sig-
nificantly changed is already shown in S1 Fig Red columns–nonresponders (patients 1–8); blue
columns–responders (patients 9–14).
(TIF)
S3 Fig. miR-148b-5p and miR-25-3p ΔΔ CT changes in patients 1–14. ΔΔ CT change for the
significantly changed from the “Treatment comparison non-responsive subjects” column in
Table 1 are shown for individual patients (listed on x-axis). miR-375 (not shown), which signif-
icantly changed is already shown in S1 Fig Red columns–nonresponders (patients 1–8); blue
columns–responders (patients 9–14).
(TIF)
S4 Fig. miR-616-5p, and miR-532-3p ΔΔ CT changes in patients 1–14. ΔΔ CT change for the
significantly changed from the “Treatment comparison in responsive subjects” column in
Table 1 are shown for individual patients (listed on x-axis). miR-148b-5p (not shown), which
significantly changed is already shown in S2 Fig Red columns–nonresponders (patients 1–8);
blue columns–responders (patients 9–14).
(TIF)
S1 File. Data used to create Fig 4 and Table 1.
(XLSX)
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